- Home
- PRME vs LOCO Comparison
PRME vs LOCO Comparison
Compare PRME & LOCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRME | LOCO |
|---|---|---|
| Founded | 2019 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.4M | 411.3M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PRME | LOCO |
|---|---|---|
| Price | $3.43 | $15.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | $7.56 | ★ $14.17 |
| AVG Volume (30 Days) | ★ 2.5M | 313.5K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.18 | 4.65 |
| EPS | N/A | ★ 0.27 |
| Revenue | $4,632,000.00 | ★ $401,701,000.00 |
| Revenue This Year | $7.06 | $3.60 |
| Revenue Next Year | $47.01 | $3.98 |
| P/E Ratio | ★ N/A | $51.67 |
| Revenue Growth | ★ 55.28 | 5.68 |
| 52 Week Low | $1.18 | $8.99 |
| 52 Week High | $6.94 | $15.90 |
Technical Indicators
Market Signals| Indicator | PRME | LOCO |
|---|---|---|
| Relative Strength Index (RSI) | 56.24 | 71.49 |
| Support Level | $3.15 | $10.22 |
| Resistance Level | $3.60 | $15.90 |
| Average True Range (ATR) | 0.23 | 0.47 |
| MACD | 0.06 | 0.10 |
| Stochastic Oscillator | 81.97 | 80.52 |
Price Performance
Historical ComparisonAbout PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
About LOCO El Pollo Loco Holdings Inc.
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. It specializes in fire-grilling citrus-marinated chicken and operates in the limited service restaurant market segment. Its offerings include Mexican-inspired menu items, including burritos, tostadas, bowls, salads, and bone-in chicken meals in various portion sizes. It also offers citrus-marinated fire-grilled chicken, along with a range of salsas and dressings that allow customers to customize their meals. The company operates in one operating segment. The majority of the company's revenue is derived from company-operated restaurant revenue.